Edinburgh Molecular Imaging Appoints Bernhard Sixt as New Chief Executive Officer

Seasoned CEO with 30 years’ experience in the healthcare industry

Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately.

Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare) and Nycomed Pharma (now part of Takeda).  Since leaving Amersham, Bernhard has led several companies. He is a co‑founder of Agendia and served as its CEO from 2003 until 2011 and in 2005 founded Ipotuba, a pioneer for addressing the emerging need for pharmaceutical cryo-logistics. He also led ImmunID, an innovator in precision immuno-oncology, from 2013 until 2016.  Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University (LMU) and a PhD from the Technical University (TU), both in Munich, Germany.

Roy Davis, Chairman of the Board of EM Imaging, said: “We are very pleased to have attracted someone of Bernhard’s calibre and I warmly welcome him to EM Imaging. Bernhard’s proven track record and experience in leading and growing companies will be invaluable in taking EM Imaging on its next stage of development.

“The board would also like to thank Ian Wilson, a former Amersham colleague of Bernhard, for his contribution in building and leading EM Imaging to its current stage.”

Bernhard Sixt, Chief Executive Officer of EM Imaging, commented: “Throughout my industry career I have always been excited by the potential that optical imaging modality offers.  I am very pleased to join EM Imaging which has the opportunity to maximise the potential offered by advanced optical imaging.  Our lead product, EMI-137, offers a “real time in situ pathology vision” to physicians and surgeons and has the potential for improved cancer detection. It has been safely administered to 69 patients so far demonstrating encouraging data and in a phase 1/2a colonoscopy study demonstrated a 17% increase in cancer lesion detection compared to standard colonoscopy, and increased detection of high risk lesions.  Currently EMI-137 is also being trialled in several other cancer indications.”


Please click here to view the original press release.